Technical Analysis for AGEN - Agenus Inc.

Grade Last Price % Change Price Change
grade D 2.88 0.35% 0.01
AGEN closed up 0.35 percent on Monday, March 18, 2019, on 49 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Up
See historical AGEN trend table...

Date Alert Name Type % Chg
Mar 18 20 DMA Resistance Bearish 0.00%
Mar 18 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Mar 18 Narrow Range Bar Range Contraction 0.00%
Mar 18 NR7 Range Contraction 0.00%
Mar 18 Inside Day Range Contraction 0.00%
Mar 15 20 DMA Resistance Bearish 0.35%
Mar 15 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.35%
Mar 15 MACD Bullish Signal Line Cross Bullish 0.35%
Mar 15 Earnings Movers Other 0.35%
Mar 15 Inside Day Range Contraction 0.35%

Older signals for AGEN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. Its technology portfolio consists of saponin adjuvant based technologies and heat shock protein based technologies. The company offers Oncophage vaccine for the treatment of renal cell carcinoma in patients at intermediate risk of recurrence. Its products under development include QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of malaria, melanoma, non-small cell lung cancer, and shingles, as well as for the treatment of various infectious diseases, multiple cancer types, and Alzheimer's disease; and HerpV, a therapeutic vaccine candidate that is in Phase 2 clinical trial for the treatment of genital herpes. The company's products under development also comprise Prophage series of cancer vaccines, including R-series candidates in RCC, M-series candidates in melanoma, and G-series candidates in glioma. Its Prophage series of cancer vaccines were tested in Phase III clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and are in Phase I and Phase II clinical trials for various indications, and in Phase II clinical trials for the treatment of diagnosed and recurrent glioma. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Medicine Health Biotechnology Cancer Clinical Medicine Infectious Diseases Cancers Non Small Cell Lung Cancer Alzheimer's Disease Vaccination Melanoma Metastatic Melanoma Vaccine Glioma Renal Cell Carcinoma Malaria Cancer Vaccines Oncophage Shingles Experimental Cancer Treatments Genital Herpes Herpes Simplex Research
Is AGEN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.89
52 Week Low 1.54
Average Volume 1,797,503
200-Day Moving Average 2.4399
50-Day Moving Average 3.2258
20-Day Moving Average 2.9355
10-Day Moving Average 2.836
Average True Range 0.2065
ADX 20.29
+DI 14.6807
-DI 17.439
Chandelier Exit (Long, 3 ATRs ) 3.0705
Chandelier Exit (Short, 3 ATRs ) 3.2395
Upper Bollinger Band 3.2254
Lower Bollinger Band 2.6456
Percent B (%b) 0.4
BandWidth 19.75132
MACD Line -0.0945
MACD Signal Line -0.0983
MACD Histogram 0.0038
Fundamentals Value
Market Cap 287.17 Million
Num Shares 99.7 Million
EPS -1.26
Price-to-Earnings (P/E) Ratio -2.29
Price-to-Sales 8.62
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.03
Resistance 3 (R3) 3.03 2.99 3.01
Resistance 2 (R2) 2.99 2.95 2.99 3.00
Resistance 1 (R1) 2.93 2.92 2.96 2.93 2.99
Pivot Point 2.89 2.89 2.90 2.89 2.89
Support 1 (S1) 2.83 2.85 2.86 2.83 2.77
Support 2 (S2) 2.79 2.82 2.79 2.76
Support 3 (S3) 2.73 2.79 2.76
Support 4 (S4) 2.73